

Received: 2020.12.04 Accepted: 2021.03.09 Available online: 2021.04.22 Published: 2021.08.10

e-ISSN 1643-3750 © Med Sci Monit. 2021: 27: e930257 DOI: 10.12659/MSM.930257

A Novel Substrate-Inspired Fluorescence-Based **Albumin Detection Improves Assessment of Clinical Outcomes in Hemodialysis Patients Receiving a Nursing Nutrition Intervention**

Authors' Contribution:

Study Design A Data Collection B

Statistical Analysis C

Data Interpretation D

Manuscript Preparation E

Literature Search F Funds Collection G ABCE Lei You* BDEG Xia Wang*

Wenhong Wang

Blood Purification Center, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, PR China

* Lei You and Xia Wang contributed equally to this work

Corresponding Author: Financial support: Wenhong Wang, e-mail: 13591355825@163.com This project was supported by the Youth Fund of Liaoning Provincial Education Department (Natural Science) (Grant No. LG2017047)

Background:

Albumin level does not precisely reflect nutritional status. We aimed to investigate the impact of a nutrition intervention on hemodialysis patients by use of fluorescence-based plasma albumin (FPA) detection.

Material/Methods:

Eighty patients underwent maintenance hemodialysis for more than half a year and had a mean albumin <3.5 g/dL for over 3 months. The subjects were randomly divided into either a Control Group (CG) or an Intervention Group (IG). The IG received nutritional supplementation, and the CG group received routine nutritional support for 12 months. FPA and plasma albumin (PA) concentrations were measured. The fluorescence probe 1,3-Dichloro-7hydroxy-9,9-dimethyl-2(9H)-acridone methyl biphenyl benzoate was used in FPA detection. Quality of life was estimated using WHOQOL-BREF (Quality of Life Scale developed through the World Health Organization), the 36-Item Short-Form Survey (SF-36), and the 6-minute walking test (6MWT).

Results:

After a 6-month and a 12-month intervention, PA and FPA concentrations increased, and the increase in FPA concentration was higher than that of PA in the IG group (P<0.05). Comparatively, the parameters of quality of life and 6MWT were improved in the IG group (P<0.05) but there were only minor changes in the CG group (P>0.05). There is an obvious association between the changes in FPA concentration and the parameters of quality of life and 6MWT but not PA.

Conclusions:

Use of the fluorescence probe improves the detection sensitivity of plasma albumin and provides a potential method to assess clinical outcomes in hemodialysis patients.

Keywords:

Fluorescent Antibody Technique, Direct • Hemodialysis Solutions • Nutrition Assessment • **Serum Albumin**

Full-text PDF:

https://www.medscimonit.com/abstract/index/idArt/930257











Background

High rates of nutritional deficiency are widely reported in patients undergoing maintenance hemodialysis [1,2]. Malnutrition can cause micro-inflammatory reactions, leading to malnutrition-inflammation-atherosclerosis syndrome (MIA) and cardio-vascular events, seriously affecting the lifespan and the general wellbeing of patients [3,4]. An optimal diet is critical to improve the outcomes of hemodialysis patients [5,6]. Albumin reflects the nutrition status of patients, and low plasma albumin (PA) is often associated with poor clinical outcomes [7]. Therefore, albumin management is often tried in various hemodialysis modalities [8]. However, the most appropriate level of albumin for nutrition assessment remains unclear. The connection between albumin and nutrition is tenuous and likely confounded by comorbid diseases [9].

A variety of albumin measurement methods have been developed, including dye binding [10], size exclusion [11], and immunoassay [12]. However, size exclusion has poor selectivity when compared with other chromatographic techniques. Immunoassay is often affected by the experimental situation, such as the incubation time and incubation temperature. The dye binding method is non-specific for human serum albumin detection, is often reversible, and is easily affected by high-affinity endogenous molecules (such as bilirubin or bile acid) and exogenous substances (such as drugs or food additives) [14]. In addition, dye binding, size exclusion, and immunoassay cannot distinguish between natural and denatured albumin. Reactive probes are usually designed based on the recognizing, binding, and catalytic characteristics of a given enzyme molecule, and thus will improve the selectivity of the detection of the target molecule. Thus, it may be important to develop an alternative method, such as human albumin reactive probe molecules (ABPs) for specifically detecting natural albumins in complex biological systems.

Based on a previous report [15], we decided to use high-sensitivity and high-specificity fluorescent probes such as 1,3-Dichloro-7-hydroxy-9,9-dimethyl-2(9H)-acridone methyl biphenyl benzoate (DDAMBB) for albumin detection. We aimed to investigate the efficiency of FPA probing in patients on maintenance hemodialysis, and to use this method to assess the nutrition deficiency in the subjects to provide an early nursing nutritional intervention. The relationship between the wellbeing or physical activity of patients and FPA or PA levels was also investigated.

Material and Methods

Participants

From July 2017 to June 2019, 360 patients on maintenance hemodialysis in the Outpatient Department of the First Affiliated Hospital of Dalian Medical University were recruited as the research subjects. After the implementing the inclusion and exclusion criteria, 80 patients were enrolled in the study (**Figure 1**). All subjects gave informed consent to participate in this study and signed an informed consent form. The study was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University.

Inclusion Criteria

The patients were 18-60 years of age, underwent maintenance hemodialysis for at least 6 months, had mean albumin <3.5 g/dL for over 3 months, and had kidney failure, which was confirmed using the values of estimated glomerular filtration rate (eGFR) less than 15 mL/min/1.73 m² [16]. eGFR was evaluated via the abbreviated Modification of Diet in Renal Disease (MDRD) formula: $186 \times (Creatinine/88.4)^{-1.154} \times (Age)^{-0.20} \times (0.742 \text{ if female})$.

Exclusion Criteria

Hepatic insufficiency was confirmed by using plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), which were over 2 times the upper limit of the normal range. We also excluded patients for drug and alcohol abuse and acute infection. Women were excluded if they were experiencing pregnancy or lactation. Chronic kidney disease (CKD) and life-threatening complications can be caused by dialysis. Kidney transplantation was performed within 3 months, and the expected survival time was ≤1 year.

Sample Size Calculation

The number of individual samples needed was calculated using the equation [17]:

$$n=2(Z_{\alpha}+Z_{1-\beta})^{2\sigma^2}/\Delta^2$$
,

where n stands for mandatory sample number, Z_{α} stands for a constant-reference based on the accepted α error, $Z_{1-\beta}$ is a constant-reference based on the power in the present research. σ presents the standard deviation (S.D.), and Δ presents the difference in effects between the Intervention and Control groups. The significance level (α error level) was 0.05 and the power was 0.8. Z_{α} is 1.96 based on a two-tailed test and $Z_{1-\beta}$ is 0.84. The noise refers to Gaussian distribution centered on zero with the S.D. of 0.5 [18]. The S.D. σ is 0.8 based on reported literature [19]. For Δ , an effect size of 0.3 is often considered as small [20]. The desired number of subjects were 65, and 80 patients were finally selected to allow for a 15% loss of patients to follow-up [21].




Figure 1. The present study CONSORT (Consolidation of Standards for Reporting Trials).

Randomization

A total of 360 patients on maintain hemodialysis at our hospital were recruited. According to the selecting standards, 80 subjects were finally selected. Random numbers were generated by a computer. According to the number, the patients were divided into a nutritional Intervention group (IG) and a Control group (CG). The patients received nutritional supplementation in the IG group, and the patients received routine nutritional support in the CG group for 12 months.

Nutritional Nursing Intervention

For both groups, the nursing staff provided routine care for the patients based on routine albumin detection, including condition observation, nutrition and diet guidance, and medication guidance. Nursing staff conducted nutritional care interventions for the patients that included the following aspects. First, they distributed health education manuals and assisted patients in formulating a reasonable diet plan, told them how to carry out diet interventions, and help them develop reasonable eating habits. Second, according to the test results, timely interventions in nutrition and diet care were performed for the patients, who were instructed to eat less fat food, eat more fresh fruits and vegetables, eat more lean meat, milk,

eggs, fish, and other protein-rich foods to ensure the intake of various vitamins. Third, the nurses paid close attention to changes in the patient's body mass. Scientific and appropriate nutritional care can ease the patient's clinical symptoms, correct the patient's metabolic disorder, and improve the function of the patient's kidneys.

The nutritional supplementations provided to the IG group comprised carbohydrates, proteins, lipids, calcium, phosphorus, potassium, and sodium, based on a previous report [22] with modification, which is mainly from milk, eggs, sugar, and cornstarch. The nutritional supplement was prepared within 15 min of consumption using the method detailed in a previous report [22] and was offered to the patients during the first half of each hemodialysis session.

Dietary Assessment

Assessment of dietary intake is extremely important for hemodialysis patients. A semi-quantitative food frequency questionnaire was developed to assess the nutritional status according to a previously reported method before and after 6 and 12 months of intervention [23].

FPA and PA Measurement

Before and after 0 months, 6 months, and 12 months of intervention, 5 mL of blood was collected from each subject into ethylene diamine tetra-acetic acid (EDTA)-coated tubes and plasma was isolated through centrifugation at 4000×g for 10 min. PA was measured using the Human Albumin ELISA Kit (Biorbyt, MA, USA) on an automatic chemistry analyzer (Mindray, BE-2000, China).

DDAMBB was purchased from DICP (Dalian, China). We exposed 0.5% plasma and human albumin (200 mg/mL) to a series of concentrations of DDABP (0.2-20 µM) in phosphate buffer (pH=7.4, 100 mM) at 37°C for 30 min. The reaction was ended by adding ice-cold acetonitrile. Metabolite was detected by measuring the fluorescence value at 662 nm. The amounts of the product per unit time represented the rate of the enzymecatalyzed reaction. Kinetic parameters (Km and Vmax) were calculated using GraphPad Prism 8.0 software. Plasma was diluted by 200 times and mixed with probe DDAMBB (final concentration 10 nM) in a 200 µL buffer reaction system, reacted at 37°C for 30 min, and an equal volume of ice-cold acetonitrile was added to stop the reaction. We used 200 nL of reaction solution for fluorescence detection (excitation/emission: 600/662 nm). The FPA content was then calculated based on the standard curve, which was made using standard albumin.

Measurement of Biochemical Parameters

The plasma total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured using kits from Shenggong Company (Shanghai, China). C-reactive protein (CRP) was evaluated using a kit (Beyotime, Beijing, China). Plasma creatinine was measured using a kit (BioVision, Milpitas, CA, USA). Adiponectin concentration was measured using ELISA (Kaibun Biotech, Shanghai, China). HbA1c (%) was measured using a HbA1c commercial kit (Recipe Chemicals – Instruments GmbH, Munich, Germany). AST and ALT were measured using kits from Shino-Test Corp. (Tokyo, Japan).

Assessments of Life Quality and Physical Activity

World Health Organization Quality of Life (WHOQOL-BREF) questionnaire was used to measure the quality of life, which consists of 4 domains (Physical health, Psychological, Social relationships, and Environment) in the WHOQOL-BREF questionnaire [24]. For the assessment of quality of life, the SF-36 questionnaire (36-Item Short-Form Health Survey) was also used to measure patients' health status. The SF-36 has 36 items comprising physical function (PF), social function (SF), role physical (RP), role emotional (RE), mental health (ME), vitality (VT), body pain (BP), and general health (GH) [22]. Physical activity

was measured using the 6-minute walking test (6MWT), which assesses how far a patient can walk in 6 minutes.

Statistical Analysis

The Shapiro-Wilk test was used to confirm the normal distribution of continuous variables, which were described as mean \pm standard deviation (S.D.). The differences between the 2 groups were assessed using the t test on 2 paired samples and Wilcoxon's test at a significance level of P < 0.05. Pearson correlation coefficient was used to evaluate the association between FPA or PA and the parameters of quality of life or physical activity. The data were processed using SPSS 20.0 software (IBM, IL, USA), and the statistical difference was significant if P < 0.05.

Results

Demographic Characteristics

Three hundred and sixty hemodialysis patients visited the outpatient department of our hospital and the final 80 patients were selected. After a 6-month intervention, 1 patient was transferred to another center and 1 patient declined to take part further in the IG group and 1 patient was transferred to another center in the CG group. After a 12-month intervention, 1 was transferred to another center and 2 patients died in the IG group and 3 patients were transferred to another center and 3 patients died in the CG group. Therefore, 35 patients in the IG group and 33 patients in the CG group finished the present study. The statistical differences for demographic variables were insignificant between the IG and CG groups, including gender, age, duration of CHD disease, smoking, drinking, lipid profile, medical treatment, the cases of tunneled central venous catheter (TVC), arteriovenous fistula (AVF), anuric and albuminuria, and other biochemical indices between IG and CG groups (**Table 1**, *P*>0.05).

Dietary Supplementation Changed Nutritional Parameters

The statistical difference for the dietary intake was insignificant between the 2 groups at 0 month (**Table 2**, P > 0.05). After a 6-month intervention, the contents of sugar, proteins, lipids, calcium, phosphorus, and potassium in the IG group were higher than those in the CG group (**Table 2**, P < 0.05). After a 12-month intervention, the levels of sugars, proteins, lipids, calcium, phosphorus, and potassium in the IG group were higher than those in the CG group (**Table 2**, P < 0.05). The results suggest that nutritional supplement changed nutritional status in the IG group when compared to that in the CG group.

Table 1. Clinical baseline characteristics between the 2 groups.

Parameters	IG, n=35	CG, n=33	P values
Age	48.9±10.7	47.45±11.3	0.681
Male/Female	20/15	20/13	0.772
Hemodialysis duration, years	3.52±2.06	3.37±2.52	0.321
Smoking, n (%)	7 (20.0)	8 (24.2)	0.673
Drinking, n (%)	6 (17.1)	5 (15.2)	0.824
TC (mg/dL)	169.6±23.5	161.9±25.4	0.531
HDL-C (mg/dL)	54.8±16.4	51.6±13.3	0.314
LDL-C (mg/dL)	94.5±22.1	89.5±22.6	0.273
TG (mg/dL)	114.8±26.7	110.2±23.9	0.164
CRP (µg/mL)	5.8±3.6	6.1±3.4	0.198
Adiponectin (µg/mL)	8.7±2.9	8.3±2.4	0.207
AST (IU/L)	24.8±6.7	23.2±5.9	0.185
ALT (IU/L)	18.9±4.3	19.4±5.5	0.298
Plasma creatinine (µM)	354.6±48.7	361.2±50.3	0.293
HbA1c (%)	5.8±0.5	5.7±0.6	0.592
Lipid-lowering agents, cases (%)			
Statin	23 (65.7) 22 (66.7)		
Fibrate	3 (8.6)	2 (6.1)	
Nicotinic acid and derivatives	2 (5.7)	1 (3.0)	0.934
Anion exchange resin	2 (5.7)	3 (9.1)	
Others	5 (14.3)	6 (18.2)	
Antiplatelet agents, cases (%)			
Cilostazol	2 (5.7)	2 (6.1)	
Ticlopidine	2 (5.7)	2 (6.1)	
Dipyridamole	3 (8.6)	2 (6.1)	
Aspirin	24 (68.6)	25 (75.8)	0.819
Sarpogrelate	2 (5.7)	1 (3.0)	
Clopidogrel	2 (5.7)	1 (3.0)	
TVC, cases (%)	7 (20.0)	6 (18.2)	0.849
AVF, cases (%)	2 (5.7)	3 (9.1)	0.946
Anuric, cases (%)	9 (25.7)	11 (33.3)	0.491
Albuminuria, cases (%)	20 (57.1)	18 (54.5)	0.829
Serum protein (g/dL)	6.6±1.2	6.4±1.0	0.269
Serum albumin(g/dL)	2.9±0.6	2.8±0.7	0.351

TVC – tunneled central venous catheter; AVF – arteriovenous fistula. Chi-square was used for analyzing the statistical difference of count data and t-student test was used for analyzing the statistical difference of measured data. The statistical difference was insignificant if P>0.05.

Table 2. Food consumption of the hemodialysis patients according to dietary patterns (mean±standard deviation, g/day).

	IG, n=35	CG, n=33	P values	IG, n=35	CG, n=33	P values	IG, n=35	CG, n=33	P values
Parameters		0 month			6 months			12 months	
Rice	103.7±32.4	106.3±36.5	0.354	105.4±33.6	108.9±37.3	0.464	103.8±33.3	108.3±36.6	0.112
Wheat	114.9±49.3	118.8±47.9	0.112	115.6±49.6	120.8±48.4	0.116	115.1±49.5	120.3±48.7	0.107
Other cereals	55.1±10.6	51.6±9.8	0.236	56.7±11.1	52.7±10.3	0.255	58.4±11.2	54.6±10.4	0.094
Starchy tubers	50.8±10.9	48.1±11.5	0.098	53.1±11.7	49.5±12.2	0.101	52.3±11.5	49.4±11.8	0.282
Pork	20.1±3.8	18.9±3.9	0.287	21.2±3.9	22±4.4	0.337	20.9±4.8	22.7±4.3	0.045*
Beef/lamb	6.4±2.5	6.8±2.2	0.174	6.5±2.6	7.1±2.3	0.273	6.5±2.6	6.9±2.3	0.186
Poultry	5.8±10.5	4.9±9.3	0.081	6.2±1.5	5.8±1.3	0.131	5.9±1.6	5.6±1.5	0.118
Aquatic product	5.0±1.3	5.4±1.6	0.123	5.1±1.5	5.8±1.6	0.132	5.4±1.3	5.9±1.6	0.139
Milk (mL)	38.5±4.4	42.6±4.6	0.086	39.3±4.5	42.8±4.6	0.285	38.7±4.5	41±4.7	0.261
Egg	30.1±4.8	32.7±4.5	0.275	31.6±4.9	33.9±4.6	0.322	31.2±4.9	33.3±4.5	0.216
Soybean	23.7±6.5	21.9±7.1	0.218	25.2±6.6	23.7±7.2	0.374	25.1±6.7	23.5±7.2	0.143
Vegetables	199.4±63.8	188.9±60.3	0.143	201.7±66.3	196.9±62.3	0.324	205.9±63.9	192.2±60.5	0.339
Cake	6.6±2.9	6.9±2.8	0.284	6.7±3	7.1±2.9	0.266	6.6±3.1	7.0±2.8	0.193
Fruit	59.2±12.8	54.7±13.2	0.095	60.2±13.2	55.7±13.4	0.177	59.5±12.8	56.6±13.3	0.204
Nuts	5.8±10.7	6.3±11.2	0.138	6.9±1.6	7.5±1.5	0.082	6.8±1.1	7.4±1.2	0.273
Juice (mL)	25.4±7.3	23.6±5.8	0.099	26.3±7.7	24.2±6.1	0.071	26.6±7.7	25.8±6.9	0.265
Other beverages (mL)	36.4±7.3	33.1±7.9	0.192	36.6±7.4	34.9±8.1	0.188	37.5±7.4	35.4±8.1	0.194
Vegetable oil (mL)	25.8±5.5	27.3±5.1	0.183	25.9±5.7	26.8±5.6	0.306	27.1±5.6	29.2±5.3	0.139
Animal fat	17.7±6.4	18.5±5.3	0.104	18.9±6.7	20.1±5.3	0.118	18.2±6.5	19.2±5.7	0.124
				+	-		+	-	
Carbohydrates	285.6±93.7	278.4±87.5	0.361	306.6±102.6	279.7±92.2	0.041*	307.2±102.8	3275.3 <u>±</u> 87.7	0.033*
Protein	124.9±23.6	128.3±21.9	0.417	148.3±27.9	132.1±24.2	0.019*	147.6±29.5	132.5±23.4	0.015*
Lipids	53.6±10.9	56.8±10.4	0.392	69.5±11.1	58±10.6	0.012*	68.7±17.4	58.6±10.5	0.009*
Phosphorus	1.4 ±0.7	1.5±0.6	0.536	1.8±0.8	1.6±0.6	0.006*	1.8±0.7	1.6±0.8	0.031*
Calcium	0.9±0.2	0.9±0.3	0.678	1.2±0.3	0.9±0.4	0.003*	1.2±0.3	1.0±0.4	0.004*
Sodium	3.3±1.2	3.5±1.1	0.135	3.8±1.2	3.6±1.1	0.124	3.6±1.3	3.4±1.1	0.161
Potassium	2.4±1.0	2.3±1.2	0.169	2.7±1.1	2.3±1.3	0.006*	2.8±1.1	2.3±1.3	0.002*

The dietary supplementation consisted of 20 g carbohydrates, 10 g of proteins, 15 g of lipids, 0.3 g of calcium, 0.3 g of phosphorus, 0.3 g of potassium, and 0.3 g of sodium. The supplementation was prepared according to previous reported with modification [22]. * P<0.05 vs the CG group.

 Table 3. Comparison of WHOQOL-BREF and SF-36 between the 2 groups.

Parameters	IG (n=33)	CG (n=35)	P values
WHOQOL-BREF			
0 month			
Physical	10.5±2.7	11.2±2.9	0.086
Psychological	11.1±2.2	10.4±2.6	0.069
Social	10.9±2.5	10.8±2.7	0.843
Environmental	11.7±3.1	10.9±2.5	0.457
Total scores	43.8±6.3	43.0±6.4	0.119
6 months			
Physical	12.5±3.1	11.9±2.7	0.041
Psychological	11.9±2.9	10.3±3.2	0.006
Social	12.8±3.2	11.8±2.8	0.037
Environmental	12.3±2.8	12.4±3.3	0.564
Total scores	49.7±3.1	45.1±3.6	0.019
12 months			
Physical	14.2±3.6	13.4±3.0	0.032
Psychological	15.3±3.3	13.5±3.2	0.016
Social	15.8±3.1	13.9±3.4	0.012
Environmental	14.7±3.8	13.8±3.5	0.038
Total scores	60.2±10.1	54.0±5.7	0.021
SF-36			
0 month			
Physical functioning	46.6±12.7	47.6±12.7	0.516
Role physical	45.9±12.3	44.8±11.8	0.223
Bodily pain	47.2±13	48.7±13.4	0.197
General health	46.5±12.9	45.3±12.9	0.206
Vitality	48.1±14.9	46.5±13.1	0.085
Social functioning	47.3±14.7	45.2±13.1	0.066
Role emotional	47.7±15.1	46.7±14.2	0.095
Mental health	46.3±14.6	45.5±13.5	0.114
Average score	45.8 ±11.8	46.7±12.3	0.582
6 months			
Physical functioning	62.8±14.2	57.3±15.7	0.032
Role physical	60.4±12.3	56±14.1	0.041
Bodily pain	60.8±14.1	56.6±14.3	0.035
General health	60.3±13.3	56.4±14.1	0.031
Vitality	61.4±14.2	56.4±15.4	0.019

Table 3 continued. Comparison of WHOQOL-BREF and SF-36 between the 2 groups.

Parameters	IG (n=33)	CG (n=35)	P values
Social functioning	59.6±13.3	55.8±13.6	0.012
Role emotional	60.3±15.3	56.6±14.5	0.022
Mental health	59.8±13.4	55.9±13.2	0.014
Average score	61.7±13.2	55.4±15.4	0.003
12 months			
Physical functioning	73.7±15.5	64.3±18.1	0.006
Role physical	73.4±15.5	62.5±17	0.003
Bodily pain	74.2±15.9	63.1±17.8	0.002
General health	74.1±14.2	61.4±17.8	0.001
Vitality	74.7±14.3	62.5±18.9	0.002
Social functioning	73.6±13.4	61.9±18	0.001
Role emotional	73.7±13.7	62.8±19.7	0.002
Mental health	72.1±13.5	62.1±17.7	0.003
Average score	72.3±15.3	62.3±16.4	0.004

Dietary Supplementation Improved Quality of Life Parameters

The statistical difference for the WHOQOL-BREF score was insignificant between the IG and CG groups at 0 months (**Table 3**, P > 0.05). After a 6-month intervention, dietary supplementation increased the WHOQOL-BREF score in the IG group, which were higher than those in the CG group, including physical, psychological, and environment domains (**Table 3**, P < 0.05). After a 12-month intervention, the scores were further increased in the IG group and were still higher than those in the CG group (**Table 3**, P < 0.05).

The statistical difference for the SF-36 score was insignificant between the 2 groups at 0 months (**Table 3**, P > 0.05). After 6 months of intervention, dietary supplementation had increased the SF-36 score in the IG group, which were higher than those in the CG group, including Physical role function, Body pain, General health, Vitality, and Emotional role (**Table 3**, P < 0.05). After a 12-month intervention, the scores were further increased in the IG group and were still higher than those in the CG group, including all the items (**Table 3**, P < 0.05). The results suggest that nutritional supplementation improved the quality of life of the subjects in the IG group when compared with the CG group by affecting WHOQOL-BREF and SF-36 scores.

Nutritional Supplement Increased FPA Level Higher Than PA Level

The statistical difference for the PA level was insignificant at 0 months (Figure 2A, P>0.05). After a 6-month intervention, PA levels in the IG group were higher than those in the CG group (Figure 2A, P<0.05). After a 12-month intervention, the PA levels in the IG group were further increased and were higher than those in the CG group (Figure 2A, P<0.05). The different concentrations of human albumin and DDAMBB probes were mixed and reacted. As the concentration of human albumin increased, the fluorescent intensity was increased and showed the highest value at 662 nm (Figure 2B). Meanwhile, there was a perfect linear relationship between the concentrations of human albumin and fluorescent intensity (Figure 2C). The results suggested that the fluorescent probes performed well in detecting human albumin. The statistical difference for FPA level was insignificant at the 0 months (Figure 2D, P>0.05). After a 6-month intervention, the FPA levels in the IG group were higher than those in the CG group (Figure 2D, P<0.01). After a 12-month intervention, the FPA levels in the IG group were further increased and were higher than those in the CG group (Figure 2D, P<0.001). Comparatively, the increase in FPA concentration was higher than that in PA concentration in the IG group after 6-month and 12-month interventions (Figure 2E, P<0.05). These results suggest that nutritional supplementation increased FPA levels more than PA levels in the hemodialysis patients.




Figure 2. Plasma levels of albumin measured using ELISA (PA) and albumin measured using fluorescent probe (FPA) between the 2 groups. (A) PA concentration (* P<0.05 vs the IG group). (B) The fluorescent profile of DDAMBB probes mixing with different concentrations of human albumin. As the concentration of human albumin increased, the PFA increased and showed the highest value at 662 nm. (C) The linear relationship between the concentrations of human albumin and fluorescent intensity. (D) FPA concentration (** P<0.01 and *** P<0.001 vs the IG group). (E) Changes in PA and PFA concentration (g/dl) from 0 to 6 months and 12 months of intervention (* P<0.05 vs PA). The hemolysis patients were divided into either the Control Group (CG, n=35) or the Intervention Group (IG, n=33). The IG received nutritional supplementation, and the CG group received routine nutritional support. The statistical difference was insignificant for ns between the 2 groups. * P<0.05, ** P<0.01 and *** P<0.001 vs the IG group.




Figure 3. Six-minute walk test (6MWT) results in the 2 groups. The hemolysis patients were divided into either the Control Group (CG, n=35) or the Intervention Group (IG, n=33). The IG received nutritional supplementation, and the CG group received routine nutritional support. The statistical difference was insignificant for ns between the 2 groups. * P<0.05, and ** P<0.01 vs the IG group.

Nutritional Supplement Improved 6MWT

The statistical difference for 6MWT values was insignificant at 0 months (**Figure 3**, *P*>0.05). After a 6-month intervention, the 6MWT values in the IG group were higher than those in the CG group (**Figure 3**, *P*<0.05). After a 12-month intervention,

the values of 6MWT in the IG group increased and were higher than those in the CG group (**Figure 3**, *P*<0.01). The results suggest that nutritional supplementation improves physical activity and increases the values of 6MWT in hemodialysis patients.

FPA Concentration Had a Stronger Negative Relationship with CRP Level

PA concentration had a strong relationship with CRP (Figure 4A). In contrast, the concentration of FPA had a stronger relationship with CRP level since the value of rho was lower (Figure 4B). The results suggest that FPA concentration had a stronger negative relationship with the CRP level and may be a potential biomarker to predict the status of physical activity in hemodialysis subjects.

The Level of FPA Had a Strong Relationship with the Parameters of Quality of Life

PA concentration had a weak relationship with WHOQOL-BREF values with low rho values (**Figure 5A**). In contrast, the concentration of FPA had a strong relationship with WHOQOL-BREF values, since the rho values were over 0.5 (**Figure 5B**). Comparatively, the PA concentration had a weak relationship with SF-36 scores with low rho values (**Figure 5C**). In contrast, the concentration of FPA had a strong relationship with SF-36 scores since the values of rho were over 0.5 (**Figure 5D**). These results suggest that the concentration of FPA had a strong relationship with the parameters of quality of life and may be a potential biomarker to predict the quality of life in hemodialysis subjects.




Figure 4. Pearson correlation coefficient test of the relationship between plasma levels of albumin measured using ELISA (PA) or albumin measured using fluorescent probe (FPA) and the levels of CRP. (A) The relationship between CRP and PA concentration. (B) The relationship between CRP and FPA concentration. There is a strong negative relationship between the 2 variables if rho <-0.5.




Figure 5. Pearson correlation coefficient test of the relationship between the plasma levels of albumin measured using ELISA (PA) or albumin measured using fluorescent probe (FPA) and the World Health Organization Quality of Life: Brief Version (WHOQOL-BREF) or the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) scores. (A) The relationship between WHOQOL-BREF and PA concentration. (B) The relationship between WHOQOL-BREF and FPA concentration. (C) The relationship between SF-36 and PA concentration. (D) The relationship between SF-36 and FPA concentration. There is a strong relationship between the 2 variables if rho >0.5.

FPA Concentration Had a Strong Relationship with the 6MWT Values

PA concentration had a weak relationship with 6MWT values with low rho values (Figure 6A). In contrast, the concentration of FPA had a strong relationship with 6MWT values since the values of rho were more than 0.5 (Figure 6B). These results suggest that FPA concentration had a strong relationship with the 6MWT values and may be a potential biomarker to predict the status of physical activity in hemodialysis subjects.

Discussion

The results showed that nutritional supplement improved the wellbeing and walking ability in patients undergoing hemodialysis. Meanwhile, the nutritional supplementation increased the

level of PA less than the level of FPA of the patients in the IG group. The levels of FPA had a significant association with the parameters of quality of life and 6MWT but not PA. Nutritional supplementation is an effective way to promote the wellbeing of hemodialysis patients. FPA may be a potential biomarker to predict the prognosis of hemodialysis patients.

Rates of nutritional deficiency in people receiving maintenance hemodialysis are still high [2]. Malnutrition can cause microinflammatory reactions, leading to cardiovascular events, and seriously affects the survival time and quality of life of patients [25]. Healthy diets and nutritional status are very important for these patients, and maintaining a good nutritional status helps reduce the risk of kidney problems and secondary complications. Hemodialysis patients lose nutrients during dialysis and nutritional status should be considered for the treatment plan, prognosis, and wellbeing of these patients.




Figure 6. Pearson correlation coefficient test of the relationship between plasma levels of albumin measured using ELISA (PA) or albumin measured using fluorescent probe (FPA) and 6-minute walk test (6MWT). (A) The relationship between 6MWT and PA concentration. (B) The relationship between 6MWT and FPA concentration. There is a strong relationship between the 2 variables if rho >0.5.

Low-level albumin is an important cause of malnutrition [26]. To verify the stability, accuracy, and specificity of PA quantitative detection to control nutrition deficiency in hemodialysis patients, the present research was carried out. The results indicated showed that nutritional supplementation increased the level of PA. However, the Pearson correlation coefficient test showed that PA level had a weak relationship with the quality of life and physical activity, suggesting that plasma PA may not be sufficiently specific or sensitive in evaluating patient outcomes.

FPA, a form of glycated PA, has high detection sensitivity, little environmental interference, and good biocompatibility, and its sensitivity and specificity were confirmed in patients undergoing maintenance hemodialysis. The results of the present study showed no statistically significant difference in albumin level between the 2 groups of patients at 0 months after enrollment, indicating that the results of the 2 detection methods were consistent during this period. Compared with the albumin levels at 6 and 12 months after enrollment, the difference was statistically significant (Figure 2, P<0.05 and P<0.01), indicating that the FPA detection method was more sensitive and specific than the PA detection method. The differences in physical activity were statistically significant, indicating that the nursing staff provided timely early nutritional care interventions, which effectively improved the patient's wellbeing and quality of life.

CRP is an acute-phase reactant, while albumin is a negative acute-phase reactant. The level of albumin has a negative relationship with the level of CRP. Comparatively, FPA has stronger negative relationship with the levels of CRP when compared with PA (Figure 4).

Serum glycated albumin (SGA) has been used to predict all-cause mortality in dialysis patients [27,28]. Elevated levels of SGA were associated with death in patients with diabetes mellitus on hemodialysis [29]. High levels of SGA were also associated with cardiovascular outcomes and death [30]. However, the effects of the nursing nutritional intervention have seldom been studied using FPA in patients on maintenance hemodialysis. The results showed a potential predictor for the nursing results of the nutritional intervention in hemodialysis patients. Notably, the evaluated levels of FPA may be beneficial to the hemodialysis patients since the dietary supplementation increased its level (Figure 2B), improved quality of life, and increased the values of WHOQOL-BREF and SF-36 (Table 3, and Figure 3). These findings agree with earlier reports.

Some limitations should be considered in future work. It seems that all patients have a narrow duration of dialysis. The hemodialysis durations (years) were 3.52±2.06 and 3.37±2.52 in the IG and CG groups, respectively, so the duration was 1.46-5.58 and 0.85-5.89, respectively. These results may be caused by the small sample size in the present study. Furthermore, a few patients with longer duration of dialysis tended to refuse to participate in our study. The function of PA and FPA were not explored in hemodialysis patients. The detail mechanisms for the functional roles of FPA are still unknown. Nursing nutritional intervention in hemodialysis patients is often complicated and costly. The dietary supplementation was not determined based on personal appetites (the nutritional supplementation was well accepted by all the patients) or malnutrition, which was only determined by the low level of GA. Although the proportion of patients with diabetic nephropathy is increasing in long-term dialysis patients, the relationship between the level of adiponectin and the classification of diabetic nephropathy was not

explored because of the small size of the sample population in this study. Further in-depth research is needed to address these important issues in a larger dialysis population in future work.

Conclusions

This study verified the sensitivity and specificity of FPA for nursing nutritional intervention in hemodialysis patients. Based on clinical care, using FPA to assess the nutritional status of hemodialysis patients will be helpful to improve the quality of

life and physical activity of patients. Personalized nutritional supplementation can be a method to prevent nutritional deficiency. Using FPA may be a good way to assess the medical outcomes of subjects on long-term maintenance hemodialysis. The present conclusions need to be verified in studies with larger sample sizes and long-term follow-up.

Conflict of Interest

None.

References:

- Plytzanopoulou P, Papasotiriou M, Politis P, et al. Malnutrition as a risk factor for cardiac valve calcification in patients under maintenance dialysis: A cross-sectional study. Int Urol Nephrol. 2020;52(11):2205-12
- Zhou J, Yang T. The efficacy of L-carnitine in improving malnutrition in patients on maintenance hemodialysis: A meta-analysis. Biosci Rep. 2020;40(6):BSR20201639
- 3. El Ati Z, Machfar H, Boussafa H, et al. Metabolic syndrome, malnutrition, and its associations with cardiovascular and all-cause mortality in hemo-dialysis patients: Follow-up for three years. Saudi J Kidney Dis Transpl. 2020;31(1):129-35
- Huang Z, Fang J, Song A, et al. The association between self-management ability and malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: A cross-sectional study. BMC Nephrol. 2021;22(1):13
- Jasani R. Nutrition in dialysis patients. Journal of Renal Nutrition and Metabolism. 2018;4(2):48
- Jo I-Y, Kim WJ, Park HC, et al. Effect of personalized nutritional counseling on the nutritional status of hemodialysis patients. Clin Nutr Res. 2017;6(4):285-95
- Xiao S, Feng F, Liu N, et al. Preoperative albumin level is superior to albumin-globulin ratio as a predicting indicator in gastric cancer patients who underwent curative resection. Cancer Manag Res. 2019;11:9931-38
- 8. Van Gelder MK, Abrahams AC, Joles JA, et al. Albumin handling in different hemodialysis modalities. Nephrol Dial Transplant. 2018;33(6):906-13
- Krowsoski L, Yeh DD. Nutrition in the geriatric surgical patient. Principles and Practice of Geriatric Surgery. 2020;135-58
- Delanghe JR, Himpe J, De Cock N, et al. Sensitive albuminuria analysis using dye-binding based test strips. Clinica Chimica Acta. 2017;471:107-12
- Haxhiu M. Method development and validation for determination of human serum albumin monomer, dimer and other aggregates using size exclusion chromatography. Northeastern Illinois University. 2019
- Del Valle R, Cazanave Mora JM, Carrazana San Martín NL, et al. An enzyme immunoassay for determining albumin in human urine samples using an ultramicroanalytical system. J Immunoassay Immunochem. 2020;41(5):896-912
- Usoltsev D, Sitnikova V, Kajava A, et al. Systematic FTIR spectroscopy study of the secondary structure changes in human serum albumin under various denaturation conditions. Biomolecules. 2019;9(8):359
- Ge G-B, Feng L, Jin Q, et al. A novel substrate-inspired fluorescent probe to monitor native albumin in human plasma and living cells. Anal Chim Acta. 2017;989:71-79
- Sun Y. Characterization and medical application research of human albumin small molecule fluorescent probe DDABP: Masters thesis, Zhengzhou University, 2018

- Heaf J, Heiro M, Petersons A, et al. Suboptimal dialysis initiation is associated with comorbidities and uraemia progression rate but not with estimated glomerular filtration rate. Clin Kidney J. 2020;14(3):933-42
- 17. Kadam P, Bhalerao S. Sample size calculation. Int J Ayurveda Res. 2010;1(1):55-57
- Bosl WJ, Li R. The role of noise and positive feedback in the onset of autosomal dominant diseases. BMC Syst Biol. 2010;4(1):93
- Plumb TJ, Alvarez L, Ross DL, et al. Safety and efficacy of the Tablo hemodialysis system for in-center and home hemodialysis. Hemodial Int. 2020;24(1):22-28
- Amro A, Waldum-Grevbo B, von der Lippe N, et al. Symptom clusters from dialysis to renal transplantation: A five-year longitudinal study. J Pain Symptom Manag. 2016;51(3):512-19
- 21. Feng Y, Shi X, Shi J, et al. Immunogenicity, antibody persistence, and safety of the 60 µg hepatitis B vaccine in hemodialysis patients: A multicenter, randomized, double-blind, parallel-controlled trial. Expert Rev Vaccines. 2017;16(10):1045-52
- Calegari A, Barros EG, Veronese FV, et al. Malnourished patients on hemodialysis improve after receiving a nutritional intervention. J Bras Nephrol. 2011;33(4):394-401
- 23. Li Y-P, He Y-N, Zhai F, et al. [Comparison of assessment of food intakes by using 3 dietary survey methods.] Zhonghua Yu Fang Yi Xue Za Zhi. 2006;40(4):273-80 [in Chinese]
- Duarte SB, Chaveiro N, de Freitas AR, et al. Validation of the WHOQOL-Bref instrument in Brazilian sign language (Libras). Qual Life Res. 2021;30(1):303-13
- Choi SR, Lee Y-K, Cho AJ, et al. Malnutrition, inflammation, progression of vascular calcification and survival: Inter-relationships in hemodialysis patients. PLoS One. 2019;14(5):e0216415
- Fu MC, D'Ambrosia C, McLawhorn AS, et al. Malnutrition increases with obesity and is a stronger independent risk factor for postoperative complications: A propensity-adjusted analysis of total hip arthroplasty patients. J Arthroplasty. 2016;31(11):2415-21
- Copur S, Siriopol D, Afsar B, et al. Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: Meta-analysis and systematic review of a predictive biomarker. Acta Diabetol. 2020;58(1):81-91
- Hayashi A, Takano K, Masaki T, et al. Distinct biomarker roles for HbA1c and glycated albumin in patients with type 2 diabetes on hemodialysis. J Diabetes Complications. 2016;30(8):1494-99
- Chen CW, Drechsler C, Suntharalingam P, et al. High glycated albumin and mortality in persons with diabetes mellitus on hemodialysis. Clin Chem. 2017;63(2):477-85
- Mihara A, Ohara T, Hata J, et al. Association between serum glycated albumin and risk of cardiovascular disease in a Japanese community: The Hisayama Study. Atherosclerosis. 2020;311:52-59